“Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients” (2014) Farmeconomia. Health economics and therapeutic pathways, 15(4), pp. 101–112. doi:10.7175/fe.v15i4.971.